Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASANT in Newly Diagnosed Malignant Glioma
NCT01656980Phase 3Unknown
- Sponsor
- Shandong Lanjin Pharmaceuticals
- Start
- Aug 2012
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of carmustine in malignant glioma, sponsored by Shandong Lanjin Pharmaceuticals. Status: unknown.
02
Drugs
carmustine
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT01656980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01656980.